Abstract
Biologics have revolutionized the treatment of rheumatoid arthritis (RA). However certain amount of the patients cannot achieve goal of therapy. Recently, compounds targeting the intracellular kinase, Janus kinase (JAK) have demonstrated therapeutic effects resembling biologics. Tofacitinib is the only JAK inhibitor approved for RA and during the clinical trial, increased events of herpes zoster (HZ) was observed. Incidence rate was twice as much as patients treated with conventional anti-rheumatic drug and was especially increased in Japan that was four times as much. The risk factors were age and glucocorticoid that is identical to that of common RA patients and there was nothing specific for tofacitinib. Mechanism of increased incidence of HZ and the difference in ethnicity remains unknown. Analysis of clinical trials have identified that HZ do not correlate with further adverse events. Therefore, it is extremely important to accumulate clinical data with considerable amount of patients with long term follow up including the post marketing surveillance in Japan to reveal the significance of increased HZ in RA patients.
| Original language | English |
|---|---|
| Pages (from-to) | 181-189 |
| Number of pages | 9 |
| Journal | Japanese Journal of Clinical Immunology |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- Disease modifying anti-rheumatic drugs
- Herpes zoster
- Janus kinase
- Rheumatoid arthritis
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis. / Yamaoka, Kunihiro.
In: Japanese Journal of Clinical Immunology, Vol. 39, No. 3, 2016, p. 181-189.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis
AU - Yamaoka, Kunihiro
PY - 2016
Y1 - 2016
N2 - Biologics have revolutionized the treatment of rheumatoid arthritis (RA). However certain amount of the patients cannot achieve goal of therapy. Recently, compounds targeting the intracellular kinase, Janus kinase (JAK) have demonstrated therapeutic effects resembling biologics. Tofacitinib is the only JAK inhibitor approved for RA and during the clinical trial, increased events of herpes zoster (HZ) was observed. Incidence rate was twice as much as patients treated with conventional anti-rheumatic drug and was especially increased in Japan that was four times as much. The risk factors were age and glucocorticoid that is identical to that of common RA patients and there was nothing specific for tofacitinib. Mechanism of increased incidence of HZ and the difference in ethnicity remains unknown. Analysis of clinical trials have identified that HZ do not correlate with further adverse events. Therefore, it is extremely important to accumulate clinical data with considerable amount of patients with long term follow up including the post marketing surveillance in Japan to reveal the significance of increased HZ in RA patients.
AB - Biologics have revolutionized the treatment of rheumatoid arthritis (RA). However certain amount of the patients cannot achieve goal of therapy. Recently, compounds targeting the intracellular kinase, Janus kinase (JAK) have demonstrated therapeutic effects resembling biologics. Tofacitinib is the only JAK inhibitor approved for RA and during the clinical trial, increased events of herpes zoster (HZ) was observed. Incidence rate was twice as much as patients treated with conventional anti-rheumatic drug and was especially increased in Japan that was four times as much. The risk factors were age and glucocorticoid that is identical to that of common RA patients and there was nothing specific for tofacitinib. Mechanism of increased incidence of HZ and the difference in ethnicity remains unknown. Analysis of clinical trials have identified that HZ do not correlate with further adverse events. Therefore, it is extremely important to accumulate clinical data with considerable amount of patients with long term follow up including the post marketing surveillance in Japan to reveal the significance of increased HZ in RA patients.
KW - Disease modifying anti-rheumatic drugs
KW - Herpes zoster
KW - Janus kinase
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84975092144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975092144&partnerID=8YFLogxK
U2 - 10.2177/jsci.39.181
DO - 10.2177/jsci.39.181
M3 - Review article
C2 - 27320933
AN - SCOPUS:84975092144
VL - 39
SP - 181
EP - 189
JO - Immunological Medicine
JF - Immunological Medicine
SN - 0911-4300
IS - 3
ER -